Aptevo Therapeutics Inc (APVO)

Jul 01, 2026

Grant supports Aptevo’s immunotherapy APVO-451 for solid tumors - BioWorld News

Jul 01, 2026

Jun 30, 2026

Aptevo Therapeutics Secures Grant for APVO451 Development - TipRanks

Jun 30, 2026

Jun 30, 2026

Aptevo (NASDAQ: APVO) gets $1.5M CARE Fund grant to advance APVO451 - Stock Titan

Jun 30, 2026

Jun 30, 2026

Aptevo receives $1.5M grant for cancer therapy development - Investing.com

Jun 30, 2026

Jun 30, 2026

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors - The Joplin Globe

Jun 30, 2026

Jun 28, 2026

Price to sales forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 28, 2026

Jun 28, 2026

Price to sales forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView

Jun 28, 2026

Jun 27, 2026

Price to book forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 27, 2026

Jun 27, 2026

APVO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026

Jun 27, 2026

Price to earnings forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 27, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Aptevo Therapeutics Inc. – NASDAQ:APVO - TradingView

Jun 27, 2026

Jun 27, 2026

Price to earnings forward of Aptevo Therapeutics, Inc. – MUN:AP82 - TradingView

Jun 27, 2026

Jun 26, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (NASDAQ:APVO) - TradingView

Jun 26, 2026

Jun 26, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (MUN:AP82) - TradingView

Jun 26, 2026

Jun 25, 2026

Aptevo Therapeutics, Inc. Actuals & Estimates (FWB:AP82) - TradingView

Jun 25, 2026

Jun 25, 2026

AP82 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

Aptevo Therapeutics Inc (APVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 23, 2026

Jun 22, 2026

Form 13G Aptevo Therapeutics Inc. For: 22 June By Investing.com - Investing.com South Africa

Jun 22, 2026

Jun 22, 2026

Niowave holds 12.18% of Aptevo (NASDAQ: APVO) — 151,723 shares - Stock Titan

Jun 22, 2026

Jun 22, 2026

NIOWAVE, INC. (NASDAQ: APVO) discloses 98,522 shares and $8 warrants - Stock Titan

Jun 22, 2026

Jun 18, 2026

Aptevo Therapeutics Inc (APVO) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jun 18, 2026

Jun 18, 2026

Aptevo Therapeutics Inc (APVO) Institutional Confidence - TradingKey

Jun 18, 2026

Jun 17, 2026

Aptevo Therapeutics Inc (APVO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 17, 2026

Jun 17, 2026

Aptevo Therapeutics Inc (APVO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jun 17, 2026

Jun 17, 2026

Aptevo Therapeutics Inc (APVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jun 17, 2026

Jun 17, 2026

Aptevo Therapeutics Inc (APVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

Aptevo Therapeutics Inc (APVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jun 17, 2026

Jun 16, 2026

Aptevo Therapeutics Inc (APVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jun 16, 2026

Jun 09, 2026

Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -

Jun 09, 2026

Jun 09, 2026

As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire

Jun 09, 2026

Jun 05, 2026

Aptevo reports 87% clinical benefit rate in AML trial - Investing.com

Jun 05, 2026

May 31, 2026

- The Legal Advocate

May 31, 2026

May 30, 2026

Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate

May 30, 2026

May 29, 2026

Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate

May 29, 2026

May 29, 2026

Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate

May 29, 2026

May 29, 2026

APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com

May 29, 2026

May 28, 2026

Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan

May 28, 2026

May 28, 2026

Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK

May 28, 2026

May 28, 2026

Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz

May 28, 2026

May 28, 2026

Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria

May 28, 2026

May 28, 2026

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire

May 28, 2026

May 28, 2026

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer

May 28, 2026

May 28, 2026

Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals

May 28, 2026

May 27, 2026

Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com

May 27, 2026

May 27, 2026

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks

May 27, 2026

May 27, 2026

Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus

May 27, 2026

May 27, 2026

APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate

May 27, 2026

May 27, 2026

Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter

May 27, 2026

May 27, 2026

Aptevo, Niowave form 50/50 partnership for cancer drugs By Investing.com - Investing.com Nigeria

May 27, 2026

May 27, 2026

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, I - PharmiWeb.com

May 27, 2026

May 27, 2026

Aptevo, Niowave form 50/50 partnership for cancer drugs - Investing.com

May 27, 2026

May 27, 2026

Niowave takes 7.9% Aptevo stake in cancer radiopharma tie-up - Stock Titan

May 27, 2026